After tumor inoculation for 20 days, the mice were randomly allocated into four groups and received i.v. administration of PBS (G1), LNP-CAD9 co-delivering Cas9 mRNA/scrambled sgRNA (G2), LNP-CAD9 co-delivering Cas9 mRNA/VEGFR2 sgRNA (G3), or MC3/DOTAP co-delivering Cas9 mRNA/VEGFR2 sgRNA (G4), with a total RNA dosage of 4.0 mg kg−1 (administered in two days of 2.0 mg kg−1 each injection). The gene discussed is KDR; the disease is neoplasm.